• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对于严重肢体缺血患者,腹股沟下单节段大隐静脉旁路移植术的效果优于其他自体静脉旁路移植术,尤其是在手术风险较高的患者中。

Outcome of infrainguinal single-segment great saphenous vein bypass for critical limb ischemia is superior to alternative autologous vein bypass, especially in patients with high operative risk.

作者信息

Arvela Eva, Venermo Maarit, Söderström Maria, Albäck Anders, Lepäntalo Mauri

机构信息

Department of Vascular Surgery, Helsinki University Central Hospital, Helsinki, Finland.

出版信息

Ann Vasc Surg. 2012 Apr;26(3):396-403. doi: 10.1016/j.avsg.2011.08.013. Epub 2012 Jan 27.

DOI:10.1016/j.avsg.2011.08.013
PMID:22285375
Abstract

BACKGROUND

Single-segment great saphenous vein (ssGSV) is the conduit of choice in infrainguinal bypass for critical limb ischemia (CLI). The aim of this study was to assess results of other autologous vein grafts and risk factors for graft stenosis development and graft failure. The purpose was also to evaluate outcome of patients with high operative risk undergoing infrainguinal alternative autologous vein bypass for CLI.

METHODS

We retrospectively reviewed 1,109 consecutive infrainguinal bypasses performed between 2000 and 2007 for CLI. Rate and type of operations needed to maintain graft patency were evaluated. Outcome of different types of vein grafts in terms of primary patency, assisted primary patency, secondary patency, and limb salvage was assessed using Kaplan-Meier method. Predictors of poor outcome as well as patient- and graft-related risk factors for graft revision and graft failure were analyzed using multivariate analysis.

RESULTS

Median follow-up period was 37 (0-121) months. Primary patency, assisted primary patency, secondary patency, and limb salvage at 1 and 3 years were significantly better in ssGSV graft group than in alternative autologous vein graft (AAVG) group-74.4% and 67.1% versus 53.7% and 42.0% (P < 0.0001), 82.8% and 78.2% versus 67.2% and 57.8% (P < 0.0001), 84.8% and 80.8% versus 69.9% and 61.4% (P < 0.0001), and 88.9% and 86.9% versus 83.0% and 77.2% (P < 0.0001), respectively. In multivariate analysis, non-ssGSV graft was the only independent risk factor for the graft stenosis development (relative risk [RR]: 2.62, 95% confidence interval [CI]: 1.56-4.38, P < 0.0001), for graft occlusion (RR: 2.27, 95% CI: 1.52-3.40, P < 0.0001), and for graft failure (stenosis or occlusion) (RR: 2.00, 95% CI: 1.39-2.88, P < 0.0001). Revision rate of non-ssGSV conduits was higher than that of ssGSV grafts (18% vs. 12%, P = 0.007). High-risk patients (age of >80 years, coronary artery disease, estimated glomerular filtration rate of <30 mL/min/1.73 m(2)) who underwent bypass with arm vein or spliced vein had extremely poor outcome (1-year leg salvage rate and survival rate of 71.4% and 28.6%, respectively).

CONCLUSION

The ssGSV graft is superior to any other autologous vein graft in terms of midterm patency and leg salvage. It also needs less maintenance procedures than AAVGs. Non-ssGSV graft is independent predictor of both graft stenosis development and graft failure. Acceptable patency and leg salvage rates can also be achieved with AAVGs. However, patients with high operative risk and non-ssGSV graft bypass have poor outcome.

摘要

背景

单节段大隐静脉(ssGSV)是下肢严重缺血(CLI)患者腹股沟下旁路移植术的首选血管。本研究旨在评估其他自体静脉移植物的效果以及移植物狭窄和失败的危险因素。同时评估接受腹股沟下自体静脉旁路移植术的高危CLI患者的预后。

方法

我们回顾性分析了2000年至2007年间连续进行的1109例腹股沟下旁路移植术治疗CLI的患者。评估维持移植物通畅所需的手术率和类型。采用Kaplan-Meier法评估不同类型静脉移植物的一期通畅率、辅助一期通畅率、二期通畅率和肢体挽救率。使用多因素分析评估预后不良的预测因素以及移植物翻修和失败的患者及移植物相关危险因素。

结果

中位随访期为37(0 - 121)个月。ssGSV移植物组1年和3年的一期通畅率、辅助一期通畅率、二期通畅率和肢体挽救率均显著优于其他自体静脉移植物(AAVG)组,分别为74.4%和67.1% 对比53.7%和42.0%(P < 0.0001),82.8%和78.2%对比67.2%和57.8%(P < 0.0001),84.8%和80.8%对比69.9%和61.4%(P < 0.0001),88.9%和86.9%对比83.0%和77.2%(P < 0.0001)。多因素分析显示,非ssGSV移植物是移植物狭窄(相对危险度[RR]:2.62,95%置信区间[CI]:1.56 - 4.38,P < 0.0001)、移植物闭塞(RR:2.27,95% CI:1.52 - 3.40,P < 0.0001)和移植物失败(狭窄或闭塞)(RR:2.00,95% CI:1.39 - 2.88,P < 0.0001)的唯一独立危险因素。非ssGSV血管的翻修率高于ssGSV移植物(18%对比12%,P = 0.007)。接受臂静脉或拼接静脉旁路移植术的高危患者(年龄>80岁、冠状动脉疾病、估计肾小球滤过率<30 mL/min/1.73 m²)预后极差(1年肢体挽救率和生存率分别为71.4%和28.6%)。

结论

就中期通畅率和肢体挽救而言,ssGSV移植物优于任何其他自体静脉移植物。与AAVG相比,其所需的维护程序也更少。非ssGSV移植物是移植物狭窄和失败的独立预测因素。AAVG也可实现可接受的通畅率和肢体挽救率。然而,手术风险高且采用非ssGSV移植物进行旁路移植术的患者预后较差。

相似文献

1
Outcome of infrainguinal single-segment great saphenous vein bypass for critical limb ischemia is superior to alternative autologous vein bypass, especially in patients with high operative risk.对于严重肢体缺血患者,腹股沟下单节段大隐静脉旁路移植术的效果优于其他自体静脉旁路移植术,尤其是在手术风险较高的患者中。
Ann Vasc Surg. 2012 Apr;26(3):396-403. doi: 10.1016/j.avsg.2011.08.013. Epub 2012 Jan 27.
2
Arm vein conduit vs prosthetic graft in infrainguinal revascularization for critical leg ischemia.肢体静脉移植物与人工血管在下肢缺血性疾病腔内血运重建中的应用比较。
J Vasc Surg. 2010 Sep;52(3):616-23. doi: 10.1016/j.jvs.2010.04.013. Epub 2010 Jul 7.
3
Optimal conduit choice in the absence of single-segment great saphenous vein for below-knee popliteal bypass.在缺乏单段大隐静脉的情况下,用于膝下腘动脉旁路的最佳移植物选择。
J Vasc Surg. 2012 Apr;55(4):1008-14. doi: 10.1016/j.jvs.2011.11.042. Epub 2012 Feb 24.
4
Lower extremity autologous vein bypass for critical limb ischemia is not adversely affected by prior endovascular procedure.对于严重肢体缺血,下肢自体静脉搭桥术不会受到先前血管内介入治疗的不利影响。
J Vasc Surg. 2014 Jul;60(1):129-35. doi: 10.1016/j.jvs.2014.01.013. Epub 2014 Mar 7.
5
Arm vein as an alternative autogenous conduit for infragenicular bypass in the treatment of critical limb ischaemia: a 15 year experience.臂静脉作为治疗下肢严重缺血的膝下旁路的替代自体移植物:15 年经验。
Eur J Vasc Endovasc Surg. 2014 Jun;47(6):609-14. doi: 10.1016/j.ejvs.2014.01.019. Epub 2014 Mar 6.
6
Midterm results of autologous saphenous vein and ePTFE pre-cuffed bypass surgery in peripheral arterial occlusive disease.自体大隐静脉和预袖套式ePTFE在外周动脉闭塞性疾病中的搭桥手术中期结果
Vasc Endovascular Surg. 2011 Oct;45(7):598-603. doi: 10.1177/1538574411414923. Epub 2011 Jul 14.
7
Defining utility and predicting outcome of cadaveric lower extremity bypass grafts in patients with critical limb ischemia.定义严重肢体缺血患者尸体下肢搭桥术的效用并预测其结果。
J Vasc Surg. 2014 Dec;60(6):1554-64. doi: 10.1016/j.jvs.2014.06.009. Epub 2014 Jul 16.
8
Bypass to plantar and tarsal arteries: an acceptable approach to limb salvage.绕过足底和跗骨动脉:一种可接受的肢体挽救方法。
J Vasc Surg. 2004 Dec;40(6):1149-57. doi: 10.1016/j.jvs.2004.08.037.
9
A comparison of femorocrural bypasses performed with modified heparin-bonded expanded polytetrafluorethylene grafts and those with great saphenous vein grafts to treat critical limb ischemia.使用改良肝素结合型膨体聚四氟乙烯移植物与大隐静脉移植物进行股腘动脉旁路移植术治疗严重肢体缺血的比较。
Ann Vasc Surg. 2015 Aug;29(6):1255-64. doi: 10.1016/j.avsg.2015.03.044. Epub 2015 May 27.
10
Autologous Alternative Vein Grafts for Infrainguinal Bypass in the Absence of Single-Segment Great Saphenous Vein: A Single-Center Study.自身静脉移植物在股浅动脉旁路术在单一节段大隐静脉缺失时的应用:单中心研究。
Ann Vasc Surg. 2024 Jun;103:133-140. doi: 10.1016/j.avsg.2023.12.067. Epub 2024 Feb 28.

引用本文的文献

1
Impact of Bypass Conduit and Early Technical Failure on Revascularization for Chronic Limb-Threatening Ischemia.旁路血管及早期技术失败对慢性肢体威胁性缺血血管重建的影响
Circ Cardiovasc Interv. 2025 Mar;18(3):e014716. doi: 10.1161/CIRCINTERVENTIONS.124.014716. Epub 2025 Mar 18.
2
Drug-eluting devices for lower limb peripheral arterial disease.药物洗脱装置治疗下肢外周动脉疾病。
EuroIntervention. 2024 Sep 16;20(18):e1136-e1153. doi: 10.4244/EIJ-D-23-01080.
3
The Impact of Diabetes on Vascular Disease: Progress from the Perspective of Epidemics and Treatments.
糖尿病对血管疾病的影响:从流行病学和治疗角度看进展
J Diabetes Res. 2022 Apr 8;2022:1531289. doi: 10.1155/2022/1531289. eCollection 2022.
4
Alternative autologous and biologic conduits have worse outcomes than prosthetic grafts for infrainguinal bypass in patients with chronic limb-threatening ischemia.对于患有慢性肢体威胁性缺血的患者,在膝下旁路手术中,自体和生物替代管道的治疗效果比人工血管移植物更差。
J Vasc Surg. 2022 Jul;76(1):188-195.e3. doi: 10.1016/j.jvs.2022.03.006. Epub 2022 Mar 18.
5
Diabetes mellitus was not associated with lower amputation-free survival after open revascularization for chronic limb-threatening ischemia - A nationwide propensity score adjusted analysis.糖尿病与慢性肢体威胁性缺血开放血运重建后的无截肢生存率降低无关 - 全国倾向评分调整分析。
Vasc Med. 2021 Oct;26(5):507-514. doi: 10.1177/1358863X211008249. Epub 2021 May 18.
6
Systems Approach to Discovery of Therapeutic Targets for Vein Graft Disease: PPARα Pivotally Regulates Metabolism, Activation, and Heterogeneity of Macrophages and Lesion Development.系统方法发现静脉移植物疾病的治疗靶点:PPARα 关键调节巨噬细胞的代谢、激活和异质性以及病变发展。
Circulation. 2021 Jun 22;143(25):2454-2470. doi: 10.1161/CIRCULATIONAHA.119.043724. Epub 2021 Apr 6.
7
Review: Tissue Engineering of Small-Diameter Vascular Grafts and Their In Vivo Evaluation in Large Animals and Humans.综述:小直径血管移植物的组织工程及其在大动物和人体内的体内评估。
Cells. 2021 Mar 23;10(3):713. doi: 10.3390/cells10030713.